An interventional study of Ovira Transcutaneous Electrical Nerve Stimulation Unit in Endometriosis and Pelvic Pain, sponsored by Milton S. Hershey Medical Center. Completed at 1 site in United States. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-08-04.
Sponsored by Milton S. Hershey Medical Center · Not applicable, Interventional, and Supportive care
The purpose of this study is see if Transcutaneous Electrical Nerve Stimulator (TENS) units help decrease endometriosis flare pain. TENS units have a 510K and are intended for relief of pain associated with sore or aching muscles of the lower back, arms, or legs due to strain from exercise or normal household and work activities.
Participants will complete surveys, record pain, medication use and bleeding in an online diary during endometriosis flare ups for 3 months without using the TENS unit. After the first 3 month period of time, a TENS unit will be given to participants to wear and again, record pain, medication use and bleeding in the online diary during endometriosis flare ups for and additional 3 months while using the TENS unit.
The investigators propose to conduct a clinical study to evaluate the effectiveness of TENS units on the management of endometriosis flare-related pain. Subjects will participate in a 3-month "baseline" period (no TENS unit use for endometriosis flares) followed by a 3-month "treatment" period (TENS unit use for endometriosis flares).
Potential subjects will be pre-screened in the Penn State Minimally Invasive GYN (MIGS) Surgery Clinic for pathologically diagnosed endometriosis and from the Penn State MIGS endometriosis database. Potential subjects will then be called to evaluate the remainder of the inclusion and exclusion criteria. If fulfilled, potential subjects will follow up at the enrollment visit (Visit 1) where consent is reviewed and signed. The baseline QOL and FSFI REDCap surveys will be completed at this visit. Subjects will be set up to receive automated links to complete diary entries and surveys directly in REDCap.
Prior to initiating TENS unit use for endometriosis flare-related pain, subjects will record daily entries into RedCap during episodes of endometriosis flares for 3 months. Each entry will record their VAS pain score as well as medication intake and bleeding profile.
Subjects will then be mailed the TENS unit at the 3 months mark into the study. Subjects will then complete entries with TENS use at their discretion for the following 3 months and record TENS unit use duration, frequency, and side effects in addition to the documentation of pain, medication and bleeding. At the end of the study, subjects will complete a QOL and FSFI survey.
901 studies on the registry are indexed under Endometriosis; 259 are open to participants now.
This study's enrollment of 40 is below the median of 64 across 525 interventional studies indexed under Endometriosis.
Browse Endometriosis studies →Milton S. Hershey Medical Center is the lead sponsor of 480 studies on the registry; 61 are open to participants now.
Of its 56 completed or terminated interventional studies of FDA-regulated products, 42 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
TENS device exclusion:
Subjects will be observed for 3 months (no intervention) during which time they will track endometriosis flares, followed by a 3-month intervention (TENS unit use) during endometriosis flares with diary tracking.
Device: Ovira Transcutaneous Electrical Nerve Stimulation Unit
TENS units have a wide application from treatment of chronic back pain, chronic abdominal pain, cancer pain, perioperative pain, and labor pain.19-24 TENS units have been shown to be well-tolerated with minimal side effects and have been successful in reducing pain as well as pain medication use in patients with primary dysmenorrhea, which excludes pathology such as endometriosis. 11-18 Certain TENS units have also been FDA approved for the general indication of pelvic pain.
Change in Average Daily VAS Pain Score
Daily pain during endometriosis flares were recorded using a Visual Analog Scale (VAS), a horizontal line measuring pain from 0 (no pain) to 100 (worst pain). Per subject, an average pain score was calculated for the baseline period (no TENS use) and treatment period (TENS use). Change (treatment minus baseline) was estimated within the context of a repeated measures model; change in the positive direction represents worse outcome, change in the negative direction represents improvement.
Time frame: Baseline period (months 1-3) and treatment period (months 4-6)
Change in Quality of Life Score From Baseline to End of Study Using the EHP30 Questionnaire
Change in quality of life from baseline to end of study using the Endometriosis Health Profile (EHP30) questionnaire. Scores range from 0 (best health status) to 100 (worst health status). Change (end of study minus baseline) was estimated within the context of a repeated measures model; change in the positive direction represents worse outcome, change in the negative direction represents improvement.
Time frame: Baseline and end of study (6 months)
Change in Female Sexual Function Index (FSFI) Total Score From Baseline to End of Study
Change in FSFI validated survey scores from baseline to end of study among participants who are currently partnered. FSFI total score ranges from 2.0 (poor) to 36.0 (best). Change (end of study minus baseline) was estimated within the context of a repeated measures model; change in the positive direction represents improvement, change in the negative direction represents worse outcome.
Time frame: Baseline and end of study (6 months)
| Milestone | Study Cohort for TENS |
|---|---|
| Started | 40 |
| Completed | 27 |
| Not completed | 13 |
Daily pain during endometriosis flares were recorded using a Visual Analog Scale (VAS), a horizontal line measuring pain from 0 (no pain) to 100 (worst pain). Per subject, an average pain score was calculated for the baseline period (no TENS use) and treatment period (TENS use). Change (treatment minus baseline) was estimated within the context of a repeated measures model; change in the positive direction represents worse outcome, change in the negative direction represents improvement.
| change in score on a scale | Study Cohort for TENS |
|---|---|
| Change in Average Daily VAS Pain Score | -2.29 (-8.31 to 3.73) |
Change in quality of life from baseline to end of study using the Endometriosis Health Profile (EHP30) questionnaire. Scores range from 0 (best health status) to 100 (worst health status). Change (end of study minus baseline) was estimated within the context of a repeated measures model; change in the positive direction represents worse outcome, change in the negative direction represents improvement.
| change in score on a scale | Study Cohort for TENS |
|---|---|
| Change in Quality of Life Score From Baseline to End of Study Using the EHP30 Questionnaire | -16.57 (-22.38 to -10.77) |
Change in FSFI validated survey scores from baseline to end of study among participants who are currently partnered. FSFI total score ranges from 2.0 (poor) to 36.0 (best). Change (end of study minus baseline) was estimated within the context of a repeated measures model; change in the positive direction represents improvement, change in the negative direction represents worse outcome.
| change in score on a scale | Study Cohort for TENS |
|---|---|
| Change in Female Sexual Function Index (FSFI) Total Score From Baseline to End of Study | 3.86 (-0.61 to 8.33) |
Collected over 3-month TENS intervention period. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Study Cohort for TENS | 0/40 (0%) | 0/40 (0%) | 7/40 (17.5%) |
| Event | Study Cohort for TENS |
|---|---|
| Skin irritation from use of TENS unitSkin and subcutaneous tissue disorders | 4/40 |
| Increased pain during/after TENS unit useGeneral disorders | 3/40 |
| Age, Continuous(years) | Study Cohort |
|---|---|
| Mean | 28.6 ± 6.6 |
| Sex: Female, Male(Participants) | Study Cohort |
|---|---|
| Female | 40 |
| Male | 0 |
| Ethnicity (NIH/OMB)(Participants) | Study Cohort |
|---|---|
| Hispanic or Latino | 4 |
| Not Hispanic or Latino | 36 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Study Cohort |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 3 |
| White | 34 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
Documents are hosted by the registry — open the source record to download them.
Plan to share: No
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Milton S. Hershey Medical Center